Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 16/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 14/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 14/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 8/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24461240 | 0.89 | PBRM1 (0.40) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24461408 | 0.87 | PBRM1 (0.37) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24461323 | 0.87 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24461456 | 0.86 | PBRM1 (0.46) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL30552692 | 0.85 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24461440 | 0.85 | CDK9 (0.45) | CCNT1CDK9 | |
| SCHEMBL24461358 | 0.84 | PBRM1 (0.38) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24461405 | 0.84 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24461343 | 0.84 | PBRM1 (0.38) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24461406 | 0.83 | PBRM1 (0.35) | PBRM1SMARCA2SMARCA4BRD4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2022109426-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | PBRM1 18/4885SMARCA2 14/4885SMARCA4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.